AEGiS-Reuters: Dupont gets ok to sell HIV drug in Europe

Reuters, Ltd.Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.
Click here to return to Reuters main menu


DonateNow


Dupont gets ok to sell HIV drug in Europe

Reuters NewMedia - Tuesday, June 1, 1999


WILMINGTON, Del., June 1 (Reuters) - DuPont Co.'s DuPont Pharmaceuticals division said Tuesday that it has been granted authorization to market Sustiva, its anti-HIV drug, in Europe.

Sustiva, which is taken once a day, was approved for sale in the United States last September.

It received marketing clearance in Canada in March of 1999.
990601
RE990601


Copyright © 1999 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.   Contact Reuters.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .